GlobeNewswire Inc | Mar 3, 2021 08:00AM EST

March 03, 2021

SAN DIEGO, March 03, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced thatJeffrey Stein, Ph.D., President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference, being held virtually March 9-10, 2021.

The presentation will be available on-demand beginning onTuesday, March 9, 2021, in the Investors section on the Companys website atwww.cidara.com.

About Cidara TherapeuticsCidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Companys portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases from Cidaras proprietary Cloudbreak antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visitwww.cidara.com.

INVESTOR CONTACT:Brian RitchieLifeSci Advisors(212) 915-2578britchie@lifesciadvisors.com

MEDIA CONTACT:Karen OShea, Ph.D.LifeSci Communications(929) 469-3860koshea@lifescicomms.com